

AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows:

Please replace the paragraph beginning at page 9, lines 1-11 with the following amended paragraph:

C1
FIG. 3A and 3B demonstrate the anti-atrophy effects of VPAC₁ and VPAC₂ receptor selective agonists (administered subcutaneously, 2X daily) in the mouse glucocorticoid (dexamethasone)-induced atrophy model. FIG 3A shows the anti-atrophy effects of VPAC₁ and VPAC₂ receptor selective agonists in glucocorticoid-induced atrophied tibialis anterior muscle. FIG 3B shows the anti-atrophy effects of VPAC₁ and VPAC₂ receptor selective agonists in glucocorticoid-induced atrophied medial gastrocnemius muscle. Legend for the X-axis: [[A]] 1: Saline + Dexamethasone (1.2 mg/kg/day included in the drinking water), [[B]] 2: PACAP-38 (0.1 mg/kg) + Dexamethasone + T, [[C]] 3: PACAP-38 (0.3 mg/kg) + Dexamethasone + T, [[D]] 4: VPAC₁R agonist (0.1 mg/kg) + Dexamethasone + T, [[E]] 5: VPAC₁R agonist (0.3 mg/kg) + Dexamethasone + T, [[F]] 6: VPAC₂R agonist (0.1 mg/kg) + Dexamethasone + T, [[G]] 7: VPAC₂R agonist (0.3 mg/kg) + Dexamethasone + T.